Cargando…

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

BACKGROUND: Elevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mid-region of the protein, while tau in CSF is instead composed of a series of fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicognola, Claudia, Hansson, Oskar, Scheltens, Philip, Kvartsberg, Hlin, Zetterberg, Henrik, Teunissen, Charlotte E., Blennow, Kaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871566/
https://www.ncbi.nlm.nih.gov/pubmed/33557920
http://dx.doi.org/10.1186/s13195-020-00756-6
_version_ 1783649032316387328
author Cicognola, Claudia
Hansson, Oskar
Scheltens, Philip
Kvartsberg, Hlin
Zetterberg, Henrik
Teunissen, Charlotte E.
Blennow, Kaj
author_facet Cicognola, Claudia
Hansson, Oskar
Scheltens, Philip
Kvartsberg, Hlin
Zetterberg, Henrik
Teunissen, Charlotte E.
Blennow, Kaj
author_sort Cicognola, Claudia
collection PubMed
description BACKGROUND: Elevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mid-region of the protein, while tau in CSF is instead composed of a series of fragments. One fragment species in particular, N-224, shows increased levels in AD compared to controls. In this multicentre study, we performed a clinical validation of the N-224 assay in cohorts including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD, non-AD dementias and controls. METHODS: Cohorts consisted of 30 SCD and 30 probable AD from the Amsterdam Dementia Cohort (cohort 1) and 539 controls, 195 SCD, 232 MCI, 137 AD and 253 non-AD from the Swedish BioFINDER study (cohort 2). All samples had AD core biomarkers (Aβ42, T-tau, P-tau181) measurements. N-224 was measured with an in-house ultrasensitive Simoa assay. RESULTS: N-224 levels were significantly higher in AD compared to SCD (cohort 1: p = 0.003) and in AD compared to all other diagnostic groups in cohort 2 (control, SCD, MCI and non-AD, p < 0.0001). Within the non-AD group, N-224 showed significantly lower concentrations compared to AD in Parkinson’s disease (PD, p < 0.0001), Parkinson’s disease dementia (PDD, p = 0.004), progressive supranuclear palsy (PSP, < 0.0001), multiple system atrophy (MSA, p = 0.002) and parkinsonisms not otherwise specified (NOS, p = 0.007). In cohort 1, higher concentrations of N-224 were associated to lower Mini-Mental State Examination (MMSE) scores (R(2) = 0.318, β = 0.564, p ≤ 0.0001) and could accurately identify a pathological (< 24) MMSE score (p < 0.0001, AUC = 0.824). CONCLUSIONS: N-224 tau can distinguish AD subjects from SCD and can discriminate subgroups of non-AD dementias from AD. Therefore, N-224 may be a useful addition to the tau biomarker toolbox for the study of tau species in CSF and for better understanding disease pathogenesis.
format Online
Article
Text
id pubmed-7871566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78715662021-02-09 Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias Cicognola, Claudia Hansson, Oskar Scheltens, Philip Kvartsberg, Hlin Zetterberg, Henrik Teunissen, Charlotte E. Blennow, Kaj Alzheimers Res Ther Research BACKGROUND: Elevated cerebrospinal fluid (CSF) concentrations of total tau (T-tau) and phosphorylated tau at Thr181 (P-tau181) protein are typical of Alzheimer’s disease (AD). However, the T-tau assay measures only the mid-region of the protein, while tau in CSF is instead composed of a series of fragments. One fragment species in particular, N-224, shows increased levels in AD compared to controls. In this multicentre study, we performed a clinical validation of the N-224 assay in cohorts including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD, non-AD dementias and controls. METHODS: Cohorts consisted of 30 SCD and 30 probable AD from the Amsterdam Dementia Cohort (cohort 1) and 539 controls, 195 SCD, 232 MCI, 137 AD and 253 non-AD from the Swedish BioFINDER study (cohort 2). All samples had AD core biomarkers (Aβ42, T-tau, P-tau181) measurements. N-224 was measured with an in-house ultrasensitive Simoa assay. RESULTS: N-224 levels were significantly higher in AD compared to SCD (cohort 1: p = 0.003) and in AD compared to all other diagnostic groups in cohort 2 (control, SCD, MCI and non-AD, p < 0.0001). Within the non-AD group, N-224 showed significantly lower concentrations compared to AD in Parkinson’s disease (PD, p < 0.0001), Parkinson’s disease dementia (PDD, p = 0.004), progressive supranuclear palsy (PSP, < 0.0001), multiple system atrophy (MSA, p = 0.002) and parkinsonisms not otherwise specified (NOS, p = 0.007). In cohort 1, higher concentrations of N-224 were associated to lower Mini-Mental State Examination (MMSE) scores (R(2) = 0.318, β = 0.564, p ≤ 0.0001) and could accurately identify a pathological (< 24) MMSE score (p < 0.0001, AUC = 0.824). CONCLUSIONS: N-224 tau can distinguish AD subjects from SCD and can discriminate subgroups of non-AD dementias from AD. Therefore, N-224 may be a useful addition to the tau biomarker toolbox for the study of tau species in CSF and for better understanding disease pathogenesis. BioMed Central 2021-02-08 /pmc/articles/PMC7871566/ /pubmed/33557920 http://dx.doi.org/10.1186/s13195-020-00756-6 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cicognola, Claudia
Hansson, Oskar
Scheltens, Philip
Kvartsberg, Hlin
Zetterberg, Henrik
Teunissen, Charlotte E.
Blennow, Kaj
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
title Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
title_full Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
title_fullStr Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
title_full_unstemmed Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
title_short Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
title_sort cerebrospinal fluid n-224 tau helps discriminate alzheimer’s disease from subjective cognitive decline and other dementias
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871566/
https://www.ncbi.nlm.nih.gov/pubmed/33557920
http://dx.doi.org/10.1186/s13195-020-00756-6
work_keys_str_mv AT cicognolaclaudia cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias
AT hanssonoskar cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias
AT scheltensphilip cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias
AT kvartsberghlin cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias
AT zetterberghenrik cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias
AT teunissencharlottee cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias
AT blennowkaj cerebrospinalfluidn224tauhelpsdiscriminatealzheimersdiseasefromsubjectivecognitivedeclineandotherdementias